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Which treatments are effective 
for cervical radiculopathy?
Evidence-based answer
Initial	treatment	options	comprise	rest,	
cervical	immobilization,	anti-inflammatory	
drugs	(nonsteroidal	and	steroidal),	pain	
relievers	(including	muscle	relaxants	
and	antiepileptics),	and	physical	therapy	
(strength	of	recommendation	[sor]:	B,	
cohort	studies).	as	many	as	60%	of	patients	
who	fail	initial	treatments	report	long-term	
pain	relief	with	epidural	corticosteroid	
injections	(sor:	C,	case	series).	surgery	
to	reduce	nerve	compression	can	improve	
pain	and	function,	but	has	risks	(sor:	B,	
1	randomized,	controlled	trial	[rCT]	and	
cohort	studies).	The	natural	course	of	
cervical	radiculopathy	may	be	spontaneous	
resolution	of	symptoms	within	5	years	in	
75%	of	cases	(sor:	B,	retrospective	cohort	
studies).	
Clinical commentary
Let the patient help choose the therapy 
Cervical	radiculopathy	is	often	diagnosed	in	
primary	care	patients	with	upper	extremity	
pain.	Many	patients	find	it	reassuring	to	
learn	that	symptoms	can	resolve	without	
invasive	treatments,	such	as	epidural	
injections	or	surgery.	Most	require	some	
form	of	symptom	management,	however.	
	 recognizing	that	strong	evidence	
doesn’t	favor	one	type	of	treatment	over	
another,	it’s	best	to	review	options	with	the	
patient	and	allow	him	or	her	to	share	in	the	
final	decision.	For	patients	who	can	tolerate	
nonsteroidal	anti-inflammatory	drugs	
(nsaIDs),	scheduled	dosing	for	10	to	14	
days	has	been	effective.	Physical	therapy	
can	help,	especially	patients	who’ve	had	
previous	success	with	this	treatment.	
	 soft	cervical	collars	are	seldom	used	in	
my	community.	Patients	report	that	wearing	
the	collar	draws	unwanted	attention;	the	
collar	is	often	difficult	to	properly	fit,	and	
all	in	all,	may	be	more	cumbersome	than	
helpful.	referral	for	epidural	corticosteroid	
injection	or	possible	surgery	is	usually	
reserved	for	patients	who	don’t	respond	to	
conservative	therapies.
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z Evidence summary
Initial treatments for cervical radiculopa-
thy encompass:
• rest
• cervical immobilization
•  NSAIDs
•  analgesics (including muscle relax-
ants and antiepileptics) 
• physical therapy.
Because few RCTs of these treatment 
options have been conducted,1 recom-
mendations are based primarily on co-
hort studies and clinical experience.
Analgesia: Try anticonvulsants last
No clinical trials have been published 
As many as 60% of 
patients who fail 
initial treatments 
report long-term 
pain relief with 
epidural  
corticosteroid 
injections.
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that look specifically at rest, immobiliza-
tion, or oral analgesics for cervical radic-
ulopathy. A Cochrane review of studies 
of anticonvulsants for treating acute and 
chronic pain found none that focused on 
cervical radiculopathy. The review con-
cluded that “surprisingly few trials show 
analgesic effectiveness of anticonvul-
sants,” and “anticonvulsants should be 
withheld until other interventions have 
been tried.”2
Physical therapy seems to help
No RCTs of physical therapy for cervical 
radiculopathy been reported. However, a 
case series of patients treated specifically 
for cervical radiculopathy found that 10 
of 11 patients who underwent physical 
therapy (including manual therapy, cervi-
cal traction, and strengthening exercises) 
were improved—defined as a self-report 
of being “quite a bit better”—at 6-month 
follow-up.3
A 1995 systematic, blinded review of 
RCTs of cervical traction found 3 studies. 
However, the inclusion criteria of these 
studies weren’t limited to cervical radicu-
lopathy, limiting the applicability of the 
results. The 3 RCTs showed no advan-
tages (2 studies) or modest advantages 
(1 study) for cervical traction over place-
bo or standard physical therapy without 
traction. Each study defined improve-
ment differently, but most patients in all 
groups showed improvement.4
Epidural steroids appear effective
Epidural corticosteroid injections have 
demonstrated success in both retrospec-
tive and prospective studies. One case 
series of cortisone epidural injections 
reported 60% of patients (12 of 20) 
had good or excellent response at long-
term follow-up (mean follow-up=21.2 
months; range=2–45 months). Six of the 
20 patients proceeded to surgery.5
Another series of 32 patients who had 
failed conventional treatment showed a 
62% response—defined as “good or ex-
cellent” pain relief—to epidural steroid 
injection at 14 days. At 6 months, 53% 
continued to report good or excellent 
pain relief. No significant side effects oc-
curred. The 44% of patients who didn’t 
report success also didn’t report any fur-
ther deterioration.6
Surgery can relieve pain,  
but has risks
Laminectomy to reduce nerve compres-
sion may alleviate pain and improve 
function, but it has risks. Surgical pro-
cedures for cervical radiculomyelopa-
thy have reported death rates of 0% to 
1.8%; nonfatal complications occurred 
in 1% to 8% of patients. 
A Cochrane review found only one 
RCT (N=81) that compared surgery with 
conservative treatment (physiotherapy 
and the cervical collar).7 Twenty patients 
crossed over to another treatment, in-
cluding 3 surgical patients who improved 
before surgery and 11 who did postop 
physiotherapy.8 Patients were still ana-
lyzed by intention to treat, however. 
The surgery group showed greater 
pain improvement at 3 months, as as-
sessed by visual analogue scale (0 to 
100), than the physiotherapy group 
(mean difference [MD]=−14; 95% confi-
dence interval [CI], −27.84 to −0.16) and 
the cervical collar (MD=−21; 95% CI, 
−33.32 to −8.68). At 1 year, however, no 
difference was seen between surgery and 
physiotherapy (MD=−9; 95% CI, −23.39 
to 5.39) or between surgery and the cer-
vical collar (MD=−5; 95% CI, −18.84 to 
8.84).7 
Symptoms often resolve  
spontaneously
The natural course of cervical radicu-
lopathy is uncertain, but symptoms often 
resolve with conservative measures or 
no treatment at all. A 1994 community-
based epidemiological survey of 561 pa-
tients showed that 75% of patients had a 
spontaneous symptomatic improvement 
within 5 years. Earlier studies (6 stud-
ies from 1957 to 1972) concluded that 
untreated patients wouldn’t necessarily 
develop progressive disability and that 
 
a	myelography	of	the	cervical	spine	
of	a	59-year-old	man	with	cervical	
radiculopathy	shows	C6	nerve	root		
impingement.			
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patients with severe disability sometimes 
improve without treatment.7
Recommendations
Brigham and Women’s Hospital’s 
guideline recommends treating cervical 
radiculopathy with a soft collar, rest, non-
steroidal anti-inflammatory drugs, and 
physical therapy with cervical traction. 
If initial management isn’t effective after 
6 weeks, the guideline advises referral to a 
specialist such as an orthopedic surgeon, 
neurologist, or rheumatologist. Surgical 
intervention is indicated if the patient 
shows signs of spinal cord compression 
or if pain is hindering function.9 
An evidence-based practice guideline 
from The American Society of Interven-
tional Pain Physicians states that mod-
erate evidence supports the efficacy of 
interlaminar and transforaminal steroid 
injections.10 n
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